Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.
Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.
In abstracts presented at the 64th American Society of Hematology Annual Meeting and Exposition, the investigational BTK inhibitor pirtobrutinib showed promising efficacy and safety in several types of B-cell lymphoma.
An analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition showed that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib.
The broad approval, while expected, will likely signal a milestone in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The combination of tucatinib and trastuzumab received accelerated approval from the FDA to treat adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (mCRC) that advances after treatment with specific types of chemotherapy.
Coverage from the 64th American Society of Hematology Annual Meeting and Exposition, held December 10-13, 2022, in New Orleans, Louisiana.
At the 2022 annual meeting of the American Society of Hematology (ASH), customized cancer immunotherapy treatments now share the limelight with bispecific antibodies, which made news across disease states from large B-cell lymphoma to follicular lymphoma to multiple myeloma; as their name suggests, these treatments aim at 2 targets, increasing their potency against cancer.
The combined resources of CareOregon and SCAN Group’s health plan and care delivery subsidiaries, operating under the HealthRight umbrella, will have revenues of $6.8 billion and will serve nearly 800,000 health plan members.
Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Leaders from Ochsner, Xavier, and their partners gathered on September 13, 2022, in New Orleans to offer an overview of the Healthy State initiative during a session of the Institute for Value-Based Medicine®.
Results from the ALPINE trial were presented Tuesday at a late-breaking session of the 64th American Society of Hematology Annual Meeting and Exposition, held in New Orleans, Louisiana.
Consolidation therapy with blinatumomab significantly improves overall survival (OS) in adult patients newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) who had no measurable residual disease (MRD negative) following initial treatment.
Coverage from the first day of the inaugural OneOncology Physician Leadership Conference, held November 11-13, 2022, in Nashville, Tennessee.
Nicole Gormley, MD, acting director of the Division of Hematology Products at FDA, explained that the agency wants to maintain momentum gained during the pandemic that moved clinical trials beyond the walls of academic centers.
Coverage from the Community Oncology Alliance Payer Exchange Summit, held in Tyson's Corner, Virginia, October 24-25, 2022.
Results of a phase 3 study presented Sunday found efgartigimod allowed a third of patients with immune thrombocytopenia (ITP) to quickly achieve platelet levels that signal an ability to avoid sudden bleeding events.
The Association of Community Cancer Centers' 39th National Oncology Conference took place October 12-14 in West Palm Beach, Florida.
Results from a phase 3 study of patients with acute myeloid leukemia (AML) are being presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.
Results for talquetamab presented at the 64th American Society of Hematology Annual Meeting and Exposition showed that about 70% of patients with multiple myeloma had responses.
Initial data on NTLA-2001, which is a novel investigative intravenous agent that works to prevent development of cardiac transthyretin (ATTR) amyloidosis by targeting the TTR gene and TTR protein levels, were presented at this year’s American Heart Association’s Scientific Sessions in Chicago.
The 64th American Society of Hematology (ASH) Meeting & Exposition will run Saturday through Tuesday in New Orleans, Louisiana, at the Ernest N. Morial Convention Center.
Investigators from Fred Hutchison Cancer Research Center hoped to gain insights into what factors can predict success with axi-cel in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.
Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.
During an Institute for Value-Based Medicine® event held in New York City, Samyukta Mullangi, MD, MBA, fellow in medical oncology at Memorial Sloan Kettering Cancer Center, discussed how disruptions from the COVID-19 pandemic are ushering in health care delivery reform.
Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, addresses the “huge problem” of financial toxicity among patients with cancer, which can be attributed in part to both the high price of targeted treatments and even from ordering only necessary testing.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.
